Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials
Eric L. Simpson(Oregon Health & Science University), Kristian Reich(Universität Hamburg), Jacob P. Thyssen(University of Copenhagen), Lynda Spelman(Veracity Clinical Research), Amy S. Paller(Northwestern University), Thomas Bieber(University of Bonn), Kenji Kabashima(Agency for Science, Technology and Research), Emma Guttman‐Yassky(Rockefeller University), Robert Bissonnette(Innovaderm (Canada)), Margaret Gamalo(Eli Lilly (United States)), Amy M. DeLozier(Eli Lilly (United States)), Fabio P. Nunes(Eli Lilly (United States)), Yuichiro Tsunemi(Saitama Medical University), Antonio Costanzo(Humanitas University), J.‐P. Lacour(Institut Gustave Roussy), Brett King(Yale University), Lawrence F. Eichenfield(University of California San Diego), Ricardo Galimberti(Hospital Italiano de Buenos Aires), Andreas Wollenberg(Vrije Universiteit Brussel), Lisa A. Beck(University of Rochester Medical Center), Dennis Brinker(Eli Lilly (United States)), T. Cardillo(Eli Lilly (United States)), Jonathan Janes(Eli Lilly (United States)), Jonathan I. Silverberg(George Washington University)
Cited by 377
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
|Frontiers in Oncology|2018|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2014|1.2k